Keyword: Duke University School of Medicine
The week’s biotech news included positive results from a study of Merck’s Cavatak in bladder cancer and the use of CRISPR to reverse genetic deafness.
A Duke lab at the center of a research pact with Sarepta is reporting promising results from a trial of CRISPR gene editing in mouse models of DMD.
A modified form of poliovirus seems to shrink breast tumors by latching onto a protein that's heavily expressed on the surface of some cancer cells.
Datavant will partner its 150 data sets with the three organizations' unique capabilities to drive clinical trial intelligence.
Researchers at Duke University developing a glioblastoma treatment based on poliovirus are unraveling the process by which the virus fights malignancy.
Former FDA chief Califf leads a PCORI-backed research foundation, ex-Shire exec Shepard jumped to Eisai's oncology business, and Forty Seven hired former Sandoz exec McCamish as new CEO.
Using instant wave-free ratio (iFR), a pressure-derived index, could lead to quicker, more cost-effective heart disease diagnoses and treatments.
Scientists at Duke University Medical Center, the University of North Carolina, and the biotech MacroGenics have teamed up to design a molecule with the capacity to bind HIV-infected cells and unite them with the immune system's killer T cells.